Stimuli of sensory-motor nerves terminate arterial contractile effects of endothelin-1 by CGRP and dissociation of ET-1/ETA-receptor complexes

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Meens, Merlijn J P M T ^a   Compeer, Matthijs G ^a   Hackeng, Tilman M ^a   van Zandvoort, Marc A ^a   Janssen, Ben J A ^a   de Mey, Jo G R ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA [[1 BUTYL 5 [2 [(2 CARBOXYPHENYL)METHOXY] 4 METHOXYPHENYL] 1H PYRAZOL 4 YL]METHYLENE] 6 METHOXY 1,3 BENZODIOXOLE 5 PROPANOIC ACID; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N(G) NITROARGININE METHYL ESTER; OLCEGEPANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; LASER MICROSCOPY; MESENTERIC ARTERY; NONHUMAN; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; SENSORIMOTOR FUNCTION; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ARTERIES; CALCITONIN GENE-RELATED PEPTIDE; ENDOTHELIN-1; PROTEIN BINDING; RATS; RECEPTOR, ENDOTHELIN A; SENSORY RECEPTOR CELLS;

RATTUS;

EID: 77955218930     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010917     Document Type: Article

References (60)

1. Pierce KL, Premont RT, Lefkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3: 639-650.
2. De Mey JGR, Compeer MG, Meens MJ (2009) Endothelin-1, an endogenous irreversible agonist in search of an allosteric inhibitor. Molecular and Cellular Pharmacology 5: 246-257.
3. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, et al. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415.
4. Hynynen MM, Khalil RA (2006) The vascular endothelin system in hypertension-recent patents and discoveries. Recent Pat Cardiovasc Drug Discov 1: 95-108.
5. Masaki T (2004) Historical review: Endothelin. Trends Pharmacol Sci 25: 219-224.
6. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ (2008) The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153: 1105-1119.
7. Schneider MP, Boesen EI, Pollock DM (2007) Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47: 731-759.
8. Bagnato A, Spinella F, Rosano L (2008) The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 86: 473-484.
9. Khodorova A, Navarro B, Jouaville LS, Murphy JE, Rice FL, et al. (2003) Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med 9: 1055-1061.
10. Davenport AP (2002) International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54: 219-226.
11. Maggi CA, Giuliani S, Patacchini R, Santicioli P, Rovero P, et al. (1989) The Cterminal hexapeptide, endothelin-(16-21), discriminates between different endothelin receptors. Eur J Pharmacol 166: 121-122.
12. Saeki T, Ihara M, Fukuroda T, Yamagiwa M, Yano M (1991) [Ala1,3,11,15]endothelin1 analogs with ETB agonistic activity. Biochem Biophys Res Commun 179: 286-292.
13. Takai M, Umemura I, Yamasaki K, Watakabe T, Fujitani Y, et al. (1992) A potent and specific agonist, Suc-[Glu9,Ala11,15]-endothelin-1(8-21), IRL 1620, for the ETB receptor. Biochem Biophys Res Commun 184: 953-959.
14. Kimura S, Kasuya Y, Sawamura T, Shinmi O, Sugita Y, et al. (1988) Structureactivity relationships of endothelin: importance of the C-terminal moiety. Biochem Biophys Res Commun 156: 1182-1186.
15. Lattig J, Oksche A, Beyermann M, Rosenthal W, Krause G (2009) Structural determinants for selective recognition of peptide ligands for endothelin receptor subtypes ETA and ETB. J Pept Sci 15: 479-491.
16. Randall MD, Douglas SA, Hiley CR (1989) Vascular activities of endothelin-1 and some alanyl substituted analogues in resistance beds of the rat. Br J Pharmacol 98: 685-699.
17. Sakamoto A, Yanagisawa M, Sawamura T, Enoki T, Ohtani T, et al. (1993) Distinct subdomains of human endothelin receptors determine their selectivity to endothelinA-selective antagonist and endothelinB-selective agonists. J Biol Chem 268: 8547-8553.
18. Tam JP, Liu W, Zhang JW, Galantino M, Bertolero F, et al. (1994) Alanine scan of endothelin: importance of aromatic residues. Peptides 15: 703-708.
19. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, et al. (1994) Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270: 228-235.
20. Ihara M, Ishikawa K, Fukuroda T, Saeki T, Funabashi K, et al. (1992) In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol 20 Suppl 12: S11-14.
21. Ohlstein EH, Nambi P, Hay DW, Gellai M, Brooks DP, et al. (1998) Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist. J Pharmacol Exp Ther 286: 650-656.
22. Sabaa N, de Franceschi L, Bonnin P, Castier Y, Malpeli G, et al. (2008) Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest 118: 1924-1933.
23. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, et al. (2007) Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298: 2009-2019.
24. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, et al. (1993) Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91: 1367-1373.
25. Boulanger C, Luscher TF (1990) Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 85: 587-590.
26. Vanhoutte PM (2000) Say NO to ET. J Auton Nerv Syst 81: 271-277.
27. De Mey JG, Megens R, Fazzi GE (2008) Functional antagonism between endogenous neuropeptide Y and calcitonin gene-related peptide in mesenteric resistance arteries. J Pharmacol Exp Ther 324: 930-937.
28. Plant TD, Zollner C, Kepura F, Mousa SS, Eichhorst J, et al. (2007) Endothelin potentiates TRPV1 via ETA receptor-mediated activation of protein kinase C. Mol Pain 3: 35.
29. Xie C, Wang DH (2009) Ablation of transient receptor potential vanilloid 1 abolishes endothelin-induced increases in afferent renal nerve activity: mechanisms and functional significance. Hypertension 54: 1298-1305.
30. Supowit SC, Zhao H, Hallman DM, DiPette DJ (1997) Calcitonin gene-related peptide is a depressor of deoxycorticosterone-salt hypertension in the rat. Hypertension 29: 945-950.
31. Wang Y, Wang DH (2004) Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP. Am J Physiol Heart Circ Physiol 287: H1868-1874.
32. Molero MM, Giulumian AD, Reddy VB, Ludwig LM, Pollock JS, et al. (2002) Decreased endothelin binding and [Ca2+]i signaling in microvessels of DOCAsalt hypertensive rats. J Hypertens 20: 1799-1805.
33. Meens MJ, Fazzi GE, van Zandvoort MA, De Mey JG (2009) Calcitonin generelated peptide selectively relaxes contractile responses to endothelin-1 in rat mesenteric resistance arteries. J Pharmacol Exp Ther 331: 87-95.
34. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, et al. (1994) Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A 91: 4892-4896.
35. Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, et al. (1992) Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 50: 247-255.
36. Burnstock G (2009) Autonomic neurotransmission: 60 years since sir Henry Dale. Annu Rev Pharmacol Toxicol 49: 1-30.
37. Bautista DM, Movahed P, Hinman A, Axelsson HE, Sterner O, et al. (2005) Pungent products from garlic activate the sensory ion channel TRPA1. Proc Natl Acad Sci U S A 102: 12248-12252.
38. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, et al. (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389: 816-824.
39. Deng PY, Ye F, Cai WJ, Tan GS, Hu CP, et al. (2004) Stimulation of calcitonin gene-related peptide synthesis and release: mechanisms for a novel antihypertensive drug, rutaecarpine. J Hypertens 22: 1819-1829.
40. Szallasi A, Blumberg PM (1999) Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 51: 159-212.
41. Chiba T, Yamaguchi A, Yamatani T, Nakamura A, Morishita T, et al. (1989) Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). Am J Physiol 256: E331-335.
42. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, et al. (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129: 420-423.
43. Mulvany MJ (1990) Structure and function of small arteries in hypertension. J Hypertens Suppl 8: S225-232.
44. Hilal-Dandan R, Villegas S, Gonzalez A, Brunton LL (1997) The quasiirreversible nature of endothelin binding and G protein-linked signaling in cardiac myocytes. J Pharmacol Exp Ther 281: 267-273.
45. Talbodec A, Berkane N, Blandin V, Breittmayer JP, Ferrari E, et al. (2000) Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol Pharmacol 57: 797-804.
46. Adner M, Shankley N, Edvinsson L (2001) Evidence that ET-1, but not ET-3 and S6b, ET(A)-receptor mediated contractions in isolated rat mesenteric arteries are modulated by co-activation of ET(B) receptors. Br J Pharmacol 133: 927-935.
47. Aumelas A, Kubo S, Chino N, Chiche L, Forest E, et al. (1998) Formation of native disulfide bonds in endothelin-1. Structural evidence for the involvement of a highly specific salt bridge between the prosequence and the endothelin-1 sequence. Biochemistry 37: 5220-5230.
48. Hewage CM, Jiang L, Parkinson JA, Ramage R, Sadler IH (1999) Solution structure of a novel ETB receptor selective agonist ET1-21 [Cys(Acm)1,15, Aib3,11, Leu7] by nuclear magnetic resonance spectroscopy and molecular modelling. J Pept Res 53: 223-233.
49. Conner AC, Simms J, Barwell J, Wheatley M, Poyner DR (2007) Ligand binding and activation of the CGRP receptor. Biochem Soc Trans 35: 729-732.
50. Peng X, Knapp BI, Bidlack JM, Neumeyer JL (2007) Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem 50: 2254-2258.
51. Blandin V, Vigne P, Breittmayer JP, Frelin C (2000) Allosteric inhibition of endothelin ETA receptors by 3, 5-dibromosalicylic acid. Mol Pharmacol 58: 1461-1469.
52. Nilius B, Owsianik G, Voets T, Peters JA (2007) Transient receptor potential cation channels in disease. Physiol Rev 87: 165-217.
53. Brain SD, Grant AD (2004) Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84: 903-934.
54. Morris GE, Nelson CP, Standen NB, Challiss RA, Willets JM (2010) Endothelin signalling in arterial smooth muscle is tightly regulated by G protein-coupled receptor kinase 2. Cardiovasc Res 85: 424-433.
55. Aiyar N, Disa J, Dang K, Pronin AN, Benovic JL, et al. (2000) Involvement of G protein-coupled receptor kinase-6 in desensitization of CGRP receptors. Eur J Pharmacol 403: 1-7.
56. Oksche A, Boese G, Horstmeyer A, Furkert J, Beyermann M, et al. (2000) Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Mol Pharmacol 57: 1104-1113.
57. Zemanova L, Schenk A, Hunt N, Nienhaus GU, Heilker R (2004) Endothelin receptor in virus-like particles: ligand binding observed by fluorescence fluctuation spectroscopy. Biochemistry 43: 9021-9028.
58. Stassen FR, Maas RG, Schiffers PM, Janssen GM, De Mey JG (1998) A positive and reversible relationship between adrenergic nerves and alpha-1A adrenoceptors in rat arteries. J Pharmacol Exp Ther 284: 399-405.
59. Hilgers RH, De Mey JG (2009) Myoendothelial coupling in the mesenteric arterial bed; segmental differences and interplay between nitric oxide and endothelin-1. Br J Pharmacol 156: 1239-1247.
60. Megens RT, Reitsma S, Schiffers PH, Hilgers RH, De Mey JG, et al. (2007) Two-photon microscopy of vital murine elastic and muscular arteries. Combined structural and functional imaging with subcellular resolution. J Vasc Res 44: 87-98.